Neoadjuvant Therapy
Combination Regimens
ACT
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Docetaxel: | 100 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by surgery [80]. |
Docetaxel + Carboplatin + Pertuzumab + Trastuzumab
Docetaxel: | 75 mg/m2 IV on day 1 |
Carboplatin: | AUC 6, IV on day 1 |
Pertuzumab: | 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks |
Trastuzumab: | 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks |
Repeat cycle every 21 days [81]. |
Adjuvant Therapy
Combination Regimens: HER2-negative disease
AC
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles [82]. |
ACT
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles [83]. |
ACT (weekly)
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by | |
Paclitaxel: | 80 mg/m2 IV on day 1 |
Repeat on a weekly schedule for 12 weeks [84]. |
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by | |
Paclitaxel: | 100 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles [85]. |
ACDocetaxel (weekly)
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by | |
Docetaxel: | 35 mg/m2 IV on day |
Repeat weekly for a total of 12 weeks [86]. |
TC
Docetaxel: | 75 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles [87]. |
TAC
Docetaxel: | 75 mg/m2 IV on day 1 |
Doxorubicin: | 50 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 6 cycles [88]. |
CAF
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Doxorubicin: | 60 mg/m2 IV on day 1 |
5-Fluorouracil: | 600 mg/m2 IV on day 1 |
Repeat cycle every 28 days for a total of 4 cycles [89]. |
Epirubicin + CMF
Epirubicin: | 100 mg/m2 IV on day 1 |
Repeat cycle every 21 days for 4 cycles, followed by | |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Methotrexate: | 40 mg/m2 IV on day 1 |
5-Fluorouracil: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles [90]. |
5-Fluorouracil: | 500 mg/m2 IV on day 1 |
Epirubicin: | 100 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 6 cycles [91]. |
FECDocetaxel
5-Fluorouracil: | 500 mg/m2 IV on day 1 |
Epirubicin: | 100 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 6 cycles [92], followed by | |
Docetaxel: | 100 mg/m2 IV on day 1 |
Repeat cycle every 21 days for 3 cycles. |
Dose-Dense Combination Regimens: HER2-negative disease
ACT
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles, followed by | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles [93]. | |
Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. |
ATC
Doxorubicin: | 60 mg/m2 IV on day 1 |
Repeat cycle every 2 weeks for 4 cycles, followed by | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 2 weeks for 4 cycles, followed by | |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 2 weeks for 4 cycles. | |
Administer filgrastim 5 μg/kg SC on days 3-10 of each treatment cycle [94]. |
ACDocetaxel
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles, followed by | |
Cyclophosphamide: | 75 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles [95]. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. |
Docetaxel: | 75 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles, followed by | |
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles [95]. Administer pegfilgrastim 6 mg SC on day 2 of each treatment cycle. |
Combination Regimens: HER2-positive disease
ACT + Trastuzumab
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for a total of 4 cycles, followed by | |
Paclitaxel: | 80 mg/m2 IV over 1 hour on day 1 |
Trastuzumab: | 4 mg/kg IV loading dose, then 2 mg/kg IV weekly |
Repeat weekly for 12 weeks, followed by | |
Trastuzumab: | 2 mg/kg IV weekly |
Repeat weekly for 40 weeks [96]. |
ACT + Trastuzumab (dose-dense)
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles, followed by | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 14 days for a total of 4 cycles. | |
Trastuzumab: | 4 mg/kg IV loading dose along with paclitaxel and then 2 mg/kg IV weekly |
Trastuzumab is administered for a total of 1 year [97]. |
TCH
Docetaxel: | 75 mg/m2 IV on day 1 |
Carboplatin: | AUC of 6, IV on day 1 |
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Repeat chemotherapy every 21 days for a total of 6 cycles. At the completion of chemotherapy, trastuzumab is administered at 6 mg/kg IV every 3 weeks for a total of 1 year [98]. |
Docetaxel: | 100 mg/m2 IV on day 1 |
Trastuzumab | 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV weekly |
Repeat cycle every 21 days for 3 cycles, followed by | |
5-Fluorouracil: | 600 mg/m2 IV on day 1 |
Epirubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days for 3 cycles [99]. |
Pertuzumab + Trastuzumab + Docetaxel
Docetaxel: | 75 mg/m2 IV on day 1 |
Trastuzumab: | 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks |
Pertuzumab: | 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks |
Repeat cycle every 21 days [100]. |
Single-Agent Regimens
Neratinib
Neratinib: | 240 mg PO daily |
Repeat daily for 1 year in patients following trastuzumab-based adjuvant therapy [101]. |
Ado-trastuzumab emtansine
Ado-trastuzumab emtansine: | 3.6 mg/kg IV on day 1 |
Repeat cycle every 21 days for a total of 14 cycles [102]. |
Hormonal Regimens
Tamoxifen
Tamoxifen: | 20 mg PO daily |
Repeat daily for 5 years in patients with ER+ tumors or ER status unknown [103]. |
Anastrozole: | 1 mg PO daily |
Repeat daily for 5 years in patients with ER+ tumors or ER status unknown [104]. |
Letrozole
Letrozole: | 2.5 mg PO daily |
Repeat daily for 5 years in patients with ER+ or PR+ tumors [105]. |
Tamoxifen + Letrozole [106]
Tamoxifen: | 20 mg PO daily for 5 years, followed by |
Letrozole: | 2.5 mg PO daily for 5 years |
Tamoxifen + Exemestane [107]
Tamoxifen: | 20 mg PO daily for 2-3 years, followed by |
Exemestane: | 25 mg PO daily for the remainder of 5 years |
Tamoxifen + Goserelin + Zoledronic acid
Tamoxifen: | 20 mg PO daily |
Goserelin: | 3.6 mg SC every 28 days |
Zoledronic acid | 4 mg IV every 6 months |
Continue treatment for a total of 3 years [108]. |
Anastrozole + Goserelin + Zoledronic acid
Anastrozole: | 1 mg PO daily |
Gosrelin: | 3.6 mg SC every 28 days |
Zoledronic acid | 4 mg IV every 6 months |
Continue treatment for a total of 3 years [108]. |
Olaparib
Olaparib: | 300 mg PO bid daily |
Repeat cycle every 24 days and continue treatment for 12 months [109]. |
Abemaciclib + Tamoxifen
Abemaciclib: | 150 mg PO bid for 2 years |
Tamoxifen: | 20 mg PO daily for 5 years |
Continue treatment with abemaciclib for 2 years and with tamoxifen for 5 years [110]. |
Abemaciclib + Aromatase Inhibitor
Abemaciclib: | 150 mg PO bid for 2 years |
Aromatase Inhibitor: | PO daily for five years |
Continue treatment with abemaciclib for 2 years and with aromatase inhibitor for 5 years [111]. |
Everolimus: | 10 mg PO daily |
Exemestane: | 25 mg PO daily |
Metastatic Disease
Combination Regimens: HER2-negative disease
AC
Doxorubicin: | 60 mg/m2 IV on day 1 |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days [82]. |
AT
Doxorubicin: | 50 mg/m2 IV on day 1 |
Paclitaxel: | 150 mg/m2 IV over 24 hours on day 1 |
Repeat cycle every 21 days [113]. or | |
Doxorubicin: | 60 mg/m2 IV on day 1 |
Repeat cycle every 21 days up to a maximum of 8 cycles, followed by | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 21 days until disease progression [113]. or | |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 21 days until disease progression, followed by | |
Doxorubicin: | 60 mg/m2 IV on day 1 |
Repeat cycle every 21 days up to a maximum of 8 cycles [113]. |
CAF
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Doxorubicin: | 60 mg/m2 IV on day 1 |
5-Fluorouracil: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days [89]. |
CEF
Cyclophosphamide: | 75 mg/m2 PO on days 1-14 |
Epirubicin: | 60 mg/m2 IV on days 1 and 8 |
5-Fluorouracil: | 500 mg/m2 IV on days 1 and 8 |
Repeat cycle every 28 days [114]. |
Cyclophosphamide: | 600 mg/m2 IV on day 1 |
Methotrexate: | 40 mg/m2 IV on day 1 |
5-Fluorouracil: | 600 mg/m2 IV on day 1 |
Repeat cycle every 21 days [90]. |
Capecitabine + Docetaxel (XT)
Capecitabine: | 1,250 mg/m2 PO bid on days 1-14 |
Docetaxel: | 75 mg/m2 IV on day 1 |
Repeat cycle every 21 days [115]. May decrease dose of capecitabine to 825-1,000 mg/m2 PO bid on days 1-14 to reduce the risk of toxicity without compromising clinical efficacy. |
Capecitabine + Paclitaxel (XP)
Capecitabine: | 825 mg/m2 PO bid on days 1-14 |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 21 days [116]. |
Capecitabine + Navelbine (XN)
Capecitabine: | 1,000 mg/m2 PO bid on days 1-14 |
Navelbine: | 25 mg/m2 IV on days 1 and 8 |
Repeat cycle every 21 days [116]. |
Capecitabine + Ixabepilone (XI)
Capecitabine: | 1,000 mg/m2 PO bid on days 1-14 |
Ixabepilone: | 40 mg/m2 IV on day 1 |
Repeat cycle every 21 days [117]. |
Docetaxel + Doxorubicin
Docetaxel: | 75 mg/m2 IV on day 1 |
Doxorubicin: | 50 mg/m2 IV on day 1 |
Repeat cycle every 21 days [118]. |
Doxorubicin liposome + Docetaxel
Doxorubicin liposome: | 30 mg/m2 on day 1 |
Docetaxel: | 60 mg/m2 on day 1 |
Repeat cycle every 21 days [119]. |
5-Fluorouracil: | 500 mg/m2 IV on day 1 |
Epirubicin: | 100 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days [120]. |
FEC-75
5-Fluorouracil: | 500 mg/m2 IV on day 1 |
Epirubicin: | 75 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days [121]. |
FEC-50
5-Fluorouracil: | 500 mg/m2 IV on day 1 |
Epirubicin: | 50 mg/m2 IV on day 1 |
Cyclophosphamide: | 500 mg/m2 IV on day 1 |
Repeat cycle every 21 days [121]. |
Gemcitabine + Paclitaxel
Gemcitabine: | 1,250 mg/m2 IV on days 1 and 8 |
Paclitaxel: | 175 mg/m2 IV on day 1 |
Repeat cycle every 21 days [122]. |
Carboplatin + Paclitaxel
Carboplatin: | AUC of 6, IV on day 1 |
Paclitaxel: | 200 mg/m2 IV over 3 hours on day 1 |
Repeat cycle every 21 days [123]. |
Carboplatin + Docetaxel
Carboplatin: | AUC of 6, IV day on 1 |
Docetaxel: | 75 mg/m2 IV on day 1 |
Repeat cycle every 21 days [124]. |
Paclitaxel + Bevacizumab
Paclitaxel: | 90 mg/m2 IV on days 1, 8, and 15 |
Bevacizumab: | 10 mg/kg on days 1 and 15 |
Repeat cycle every 28 days [125]. |
Atezolizumab: | 840 mg IV on days 1 and 15 |
Nab-Paclitaxel: | 100 mg/m2 IV on days 1, 8, and 15 |
Repeat cycle every 28 days [126]. |
Combination Regimens: HER2-positive disease
Pertuzumab + Trastuzumab + Docetaxel
Pertuzumab: | 840 mg IV loading dose on day 1 and then 420 mg IV every 3 weeks |
Trastuzumab: | 8 mg/kg IV loading dose on day 1 and then 6 mg/kg IV every 3 weeks |
Docetaxel: | 75 mg/m2 IV on day 1 |
Repeat cycle every 21 days [100]. |
Trastuzumab + Paclitaxel
Trastuzumab + Docetaxel
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV on days 8 and 15 |
Docetaxel: | 35 mg/m2 IV on days 1, 8, and 15 |
First cycle is administered weekly for 3 weeks, with 1 week of rest. For subsequent cycles, | |
Trastuzumab: | 2 mg/kg IV weekly |
Docetaxel: | 35 mg/m2 IV weekly |
Repeat cycle every 4 weeks [129]. |
TCH
Carboplatin: | AUC of 6, IV on day 1 |
Docetaxel: | 75 mg/m2 IV on day 1 |
Trastuzumab: | 4 mg/kg IV loading dose on day 1 and then 2 mg/kg IV on days 8 and 15, 2 mg/kg IV weekly thereafter |
Repeat cycle every 21 days [130]. |
Gemcitabine + Carboplatin + Trastuzumab
Gemcitabine: | 1,500 mg/m2 IV on day 1 |
Carboplatin: | AUC of 2.5, IV on day 1 |
Trastuzumab: | 8 mg/kg IV loading dose on day 1 and then 4 mg/kg IV every 2 weeks |
Repeat cycle every 2 weeks [131]. |
Trastuzumab + Navelbine
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Navelbine: | 25 mg/m2 IV weekly |
Repeat on a weekly basis until disease progression [132]. |
Trastuzumab + Gemcitabine
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Gemcitabine: | 1,200 mg/m2 IV weekly for 2 weeks |
Repeat cycle every 21 days [133]. |
Trastuzumab + Capecitabine
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Capecitabine: | 1,250 mg/m2 PO bid on days 1-14 |
Repeat cycle every 21 days [134]. or | |
Trastuzumab: | 8 mg/kg IV loading dose and then 6 mg/kg IV on day 1 of all subsequent cycles |
Capecitabine: | 1,250 mg/m2 PO bid on days 1-14 |
Repeat cycle every 21 days [135]. |
Trastuzumab + Lapatinib
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Lapatinib: | 1,000 mg PO daily |
Continue until disease progression [136]. |
Capecitabine + Lapatinib
Capecitabine: | 1,000 mg/m2 PO bid on days 1-14 |
1,250 mg PO daily | |
Repeat cycle every 21 days [137]. |
Capecitabine + Neratinib
Capecitabine: | 750 mg/m2 PO bid on days 1-14 |
Neratinib: | 240 mg PO daily |
Repeat cycle every 21 days [138]. |
Tucatinib + Trastuzumab + Capecitabine
Tucatinib: | 300 mg PO bid |
Trastuzumab: | 8 mg/kg IV loading dose followed by 6 mg/kg IV on day 1 |
Capecitabine: | 1,000 mg/m2 PO bid on days 1-21 |
Repeat cycle every 21 days [139]. |
Margetuximab-cmkb + Capecitabine
Margetuximab: | 15 mg/kg IV on day 1 |
Capecitabine: | 1,000 mg/m2 PO bid on days 1-14 |
Repeat cycle every 21 days [140]. |
Margetuximab-cmkb + Eribulin
Margetuximab: | 15 mg/kg IV on day 1 |
Eribulin: | 1.4 mg/m2 IV on days 1 and 8 |
Repeat cycle every 21 days [140]. |
Margetuximab-cmkb + Vinorelbine
Margetuximab: | 15 mg/kg IV on day 1 |
Vinorelbine: | 25 mg/m2 IV on days 1 and 8 |
Repeat cycle every 21 days [140]. |
Margetuximab-cmkb + Gemcitabine
Margetuximab: | 15 mg/kg IV on day 1 |
Gemcitabine: | 1,000 mg IV on days 1 and 8 |
Repeat cycle every 21 days [140]. |
Combination Regimens: Hormone-Receptor Positive, HER2-Negative Disease
Everolimus + Exemestane [112]
Everolimus: | 10 mg PO daily |
Exemestane: | 25 mg PO daily |
Palbociclib: | 125 mg PO daily for 21 days |
Letrozole: | 2.5 mg PO daily |
Repeat cycle every 21 days [141]. |
Ribociclib + Letrozole
Ribociclib: | 600 mg PO daily for 21 days |
Letrozole: | 2.5 mg PO daily |
Repeat cycle every 28 days [142]. |
Palbociclib + Fulvestrant
Palbociclib: | 125 mg PO daily for 21 days |
Fulvestrant: | 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles |
Repeat cycle every 28 days [143]. |
Abemaciclib + Fulvestrant
Abemaciclib: | 150 mg PO bid |
Fulvestrant: | 500 mg IM on days 1 and 15 of first cycle and then 500 mg IM on day 1 for all subsequent cycles |
Repeat cycle every 28 days [144]. |
Alpelisib + Fulvestrant
Alpelisib: | 300 mg PO daily |
Fulvestrant: | 500 mg IM on days 1, 15, and 29 and then once per month |
Repeat cycle every 28 days [145]. |
Abemaciclib + Anastrozole
Abemaciclib: | 150 mg PO bid |
Anastrozole: | 1 mg PO daily |
Repeat cycle every 28 days [146]. |
Abemaciclib + Letrozole
Abemaciclib: | 150 mg PO bid |
Letrozole: | 2.5 mg PO daily |
Repeat cycle every 28 days [146]. |
Single-Agent Regimens: Hormone-Receptor Positive and HER2-Positive Disease
Tamoxifen
Tamoxifen: | 20 mg PO daily [147] |
Toremifene
Toremifene: | 60 mg PO daily [148] |
Exemestane
Exemestane: | 25 mg PO daily [149] |
Anastrozole
Anastrozole: | 1 mg PO daily [150] |
Letrozole
Letrozole: | 2.5 mg PO daily [151] |
Fulvestrant
Elacestrant (ESR1 mutation)
Elacestrant: | 345 mg PO daily |
Repeat cycle every 28 days until disease progression [154]. |
Megestrol
Megestrol: | 40 mg PO qid [155] |
Trastuzumab
Trastuzumab: | 4 mg/kg IV loading dose and then 2 mg/kg IV weekly |
Repeat cycle weekly for a total of 10 weeks. In the absence of disease progression, continue weekly maintenance dose of 2 mg/kg [156]. or | |
Trastuzumab: | 8 mg/kg IV loading dose, then 6 mg/kg IV every 3 weeks |
Continue treatment until disease progression [157]. |
Margetuximab
Margetuximab: | 15 mg/kg IV on day 1 |
Repeat cycle every 21 days [158]. |
Trastuzumab and hyaluronidase
Trastuzumab and hyaluronidase: | 600 mg trastuzumab SC and 10,000 units hyaluronidase SC on day 1 |
Repeat cycle every 21 days [159]. |
Ado-trastuzumab emtansine
Ado-trastuzumab: | 3.6 mg/kg IV on day 1 |
Repeat cycle every 21 days [160]. |
Trastuzumab deruxtecan-nxki
Trastuzumab deruxtecan: | 5.4 mg/kg IV on day 1 |
Repeat cycle every 21 days [161]. |
Capecitabine
Capecitabine: | 1,250 mg/m2 PO bid on days 1-14 |
Repeat cycle every 21 days [162]. May decrease dose to 850-1,000 mg/m2 PO bid on days 1-14 to reduce risk of toxicity without compromising clinical efficacy. |
Docetaxel
Paclitaxel
Ixabepilone
Ixabepilone: | 40 mg/m2 IV on day 1 |
Repeat cycle every 21 days [167]. |
Vinorelbine: | 30 mg/m2 IV on day 1 |
Repeat cycle every 7 days [168]. |
Doxorubicin
Doxorubicin: | 20 mg/m2 IV on day 1 |
Repeat cycle every 7 days [169]. |
Gemcitabine
Gemcitabine: | 725 mg/m2 IV weekly for 3 weeks |
Repeat cycle every 28 days [170]. |
Doxorubicin liposome
Doxorubicin liposome: | 40 mg/m2 IV on day 1 |
Repeat cycle every 28 days [171]. |
Abraxane
Eribulin
Eribulin: | 1.4 mg/m2 IV on days 1 and 8 |
Repeat cycle every 21 days [174]. |
Olaparib
Olapraib: | 300 mg PO bid |
Repeat cycle every 28 days [175]. |
Talazoparib
Talazoparib: | 1 mg PO daily |
Repeat cycle every 28 days [176]. |
Sacituzumab govitecan-hziy
Sacituzumab govitecan: | 10 mg/kg IV on days 1 and 8 |
Repeat cycle every 21 days [177]. |
Single-Agent Regimens: Hormone-Receptor Positive and HER2-Negative Disease
Abemaciclib
Abemaciclib: | 150 mg PO bid |
Repeat cycle every 28 days [178]. |